On October 29th, Haoyuan Medicine (688131.SH) announced that in the first three quarters of 2024, it achieved total operating income of 1.619 billion yuan, an increase of 17.65% year-on-year; the net income attributable to the parent company's shareholders was 0.143 billion yuan, a year-on-year increase of 21.31%; and the basic earnings per share was 0.68 yuan.
皓元医药(688131.SH)：前三季度净利润1.43亿元，同比增长21.31%
Haoyuan Pharmaceutical (688131.SH): the net income in the first three quarters was 0.143 billion yuan, with a year-on-year growth of 21.31%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated